CNBC May 30, 2024
Sophie Kiderlin

Key Points

– The rise of weight loss drugs means consumers’ nutritional needs are “shifting,” Nestle CEO Mark Schneider told CNBC’s Silvia Amaro.

– Nestle is looking to capitalize on the popularity of the GLP-1 drugs with its “ambitious goal to push the healthier products,” the CEO said.

– The Swiss food and beverage giant is set to launch frozen food products targeted at GLP-1 weight loss drug users called Vital Pursuit later this year.

The meteoric rise of weight loss drugs means consumers’ nutritional needs are “shifting” which provides new opportunities for food companies, Nestle CEO Mark Schneider told CNBC.

Investors were initially concerned about the popularity of GLP-1 drugs such as Wegovy and Ozempic as it was assumed...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Provider, Retailer
The Health Care Transformation Task Force and the National Association of ACOs Suggest Ways to Improve Patient Engagement in Value-Based Care
Telemedicine can get more people to stick with addiction treatment
This Cancer Screening Approach Is Unreliable in Black Women
Reimagining Beneficiary Engagement in Accountable Care Models
What the Medicare Quality Rating Change Means for Healthcare Companies — and Patient Health

Share This Article